Medical treatment in acromegaly
Introduction
Acromegaly is a rare disfiguring condition caused by growth hormone (GH) hypersecretion usually from a pituitary somatotroph adenoma. A single GH molecule binds two identical cell-surface receptors, inducing dimerisation and stimulating production of insulin-like growth factor-I (IGF-I), which is the effector of many of the actions of GH. IGF-I is generated in many tissues and has endocrine, paracrine and autocrine actions, with circulating IGF-I being predominantly of hepatic origin (Figure 1). The morbidity and excess mortality of acromegaly are the consequence of the metabolic actions of excess GH and IGF-I secretion rather than the mass effects of the pituitary tumour, and result in the many signs and symptoms of the disease, such as lethargy, sweating, arthralgia, hypertension and diabetes mellitus. The risk of premature death is increased two- to fourfold [1]. Recent advances in medical therapy have raised the prospect of obtaining biochemical control in virtually every patient, with consequent relief of symptoms and restoration of life expectancy to normal.
Transsphenoidal surgery is the treatment of choice for most patients, with the outcome dependent on the size and invasiveness of the tumour and, in particular, the skill of the specialist pituitary surgeon. As 70% of tumours are macroadenomas, most patients are not cured by surgery and require medical treatment [2]. Radiotherapy is an option, either conventional three-field or stereotactic, but the full benefit is not seen for many years, which again necessitates medical therapy in the interim. For the past decade, the mainstay of medical treatment has been dopamine agonists and somatostatin analogues, with the latter being the gold standard against which the recently available GH receptor antagonist pegvisomant must be judged. Controlled trials have reported pegvisomant to have a superior ability at achieving biochemical disease control, but many questions about this new form of therapy remain. This review focuses on the medical therapy of acromegaly and considers the role of pegvisomant.
Section snippets
Dopamine agonists
The first effective medical treatment for acromegaly was the dopamine agonist bromocriptine, which lowers GH secretion in most patients but only achieves the desired levels of control in less than 20% of cases [3]. Alternative dopamine agonists include cabergoline and quinagolide, which have a prolonged duration of action and greater efficacy, and are also better tolerated. The largest study of cabergoline in acromegaly was conducted in 64 patients (16 with prolactin co-secreting tumours), of
Somatostatin analogues
Somatostatin analogues are the most widely prescribed medical treatment for acromegaly, usually as adjunctive therapy to surgery and/or radiotherapy but increasingly as primary therapy. Octreotide and lanreotide are cyclic octapeptide somatostatin analogues that have been in use for many years, although the latter is not available in the USA (Figure 2). Their inhibition of GH secretion is predominantly mediated via somatostatin receptor-2 and -5 subtypes expressed on the adenoma. Octreotide was
Growth hormone receptor antagonists
Pegvisomant is a GH analogue and novel form of pharmacotherapy for acromegaly. GH is a 22 kDa peptide (191 residues) that contains two disulfide bonds and four α–helices. GH acts by binding two identical cell-surface receptors to induce functional receptor dimerisation and thereby trigger second messengers and IGF-I generation. Gly120 in the third α-helix of human GH is critical for the binding of the second GH receptor, and substitution of this amino acid with a side-chain creates a GH
Conclusions
Surgery is the treatment of choice in the majority of patients with acromegaly, as it offers the prospect of rapidly lowering GH levels and a subsequent cure, as well as being cost-effective. The availability of pegvisomant will not greatly alter the use of dopamine agonists as therapy, as the advantages of these drugs are oral administration and cost. However, pegvisomant does represent a major advance in the treatment of acromegaly and will impact on the use of somatostatin analogues, which
References and recommended reading
Papers of particular interest, published within the annual period of review, have been highlighted as:
- •
of special interest
- ••
of outstanding interest
References (20)
- et al.
Treatment of acromegaly with dopamine agonists
Endocrinol. Metab. Clin. North Am.
(1992) - et al.
Lowering total plasma insulin-like growth factor 1 concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, Pegvisomant (B2036-Peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men
J. Clin. Endocrinol. Metab.
(2001) - et al.
Long-term outcome and mortality after transsphenoidal adenectomy for acromegaly
Clin. Endocrinol. (Oxf)
(2003) - et al.
Outcome of surgery for acromegaly — the experience of a dedicated pituitary surgeon
QJM
(1999) - et al.
Cabergoline in the treatment of acromegaly: a study in 64 patients
J. Clin. Endocrinol. Metab.
(1998) Somatostatin analogs in acromegaly
J. Clin. Endocrinol. Metab.
(2002)- et al.
A comparison of lanreotide and octreotide LAR for treatment of acromegaly
Clin. Endocrinol. (Oxf)
(1999) - et al.
Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly
Clin. Endocrinol. (Oxf)
(2000) - et al.
Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size
J. Clin. Endocrinol. Metab.
(2002) - Lucas T, Astorga R, Catala M, Spanish Multicentre Lanreotide Study Group on Acromegaly: Preoperative lanreotide...